mRNA vaccines for infectious diseases: principles, delivery and clinical translation

N Chaudhary, D Weissman… - Nature reviews Drug …, 2021 - nature.com
Over the past several decades, messenger RNA (mRNA) vaccines have progressed from a
scepticism-inducing idea to clinical reality. In 2020, the COVID-19 pandemic catalysed the …

The epidemiology, diagnosis and treatment of COVID-19

P Zhai, Y Ding, X Wu, J Long, Y Zhong, Y Li - International journal of …, 2020 - Elsevier
In December 2019, the outbreak of the novel coronavirus disease (COVID-19) in China
spread worldwide, becoming an emergency of major international concern. SARS-CoV-2 …

New vaccine technologies to combat outbreak situations

S Rauch, E Jasny, KE Schmidt, B Petsch - Frontiers in immunology, 2018 - frontiersin.org
Ever since the development of the first vaccine more than 200 years ago, vaccinations have
greatly decreased the burden of infectious diseases worldwide, famously leading to the …

Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases

S Wang, B Liang, W Wang, L Li, N Feng… - Signal transduction and …, 2023 - nature.com
Human diseases, particularly infectious diseases and cancers, pose unprecedented
challenges to public health security and the global economy. The development and …

[HTML][HTML] Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster …

AM Henao-Restrepo, A Camacho, IM Longini… - The Lancet, 2017 - thelancet.com
Background rVSV-ZEBOV is a recombinant, replication competent vesicular stomatitis virus-
based candidate vaccine expressing a surface glycoprotein of Zaire Ebolavirus. We tested …

mRNA vaccines for COVID-19 and diverse diseases

A Hussain, H Yang, M Zhang, Q Liu, G Alotaibi… - Journal of Controlled …, 2022 - Elsevier
Since its outbreak in late 2019, the novel coronavirus disease 2019 (COVID-19) has spread
to every continent on the planet. The global pandemic has affected human health and …

Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial

AM Henao-Restrepo, IM Longini, M Egger, NE Dean… - The Lancet, 2015 - thelancet.com
Background A recombinant, replication-competent vesicular stomatitis virus-based vaccine
expressing a surface glycoprotein of Zaire Ebolavirus (rVSV-ZEBOV) is a promising Ebola …

Ebola virus disease

D Malvy, AK McElroy, H de Clerck, S Günther… - The Lancet, 2019 - thelancet.com
Ebolaviruses are pathogenic agents associated with a severe, potentially fatal, systemic
disease in man and great apes. Four species of ebolaviruses have been identified in west or …

A recombinant vesicular stomatitis virus Ebola vaccine

JA Regules, JH Beigel, KM Paolino… - … England Journal of …, 2017 - Mass Medical Soc
Background The worst Ebola virus disease (EVD) outbreak in history has resulted in more
than 28,000 cases and 11,000 deaths. We present the final results of two phase 1 trials of an …

Phase 2 placebo-controlled trial of two vaccines to prevent Ebola in Liberia

SB Kennedy, F Bolay, M Kieh, G Grandits… - … England Journal of …, 2017 - Mass Medical Soc
Background The safety and efficacy of vaccines to prevent Ebola virus disease (EVD) were
unknown when the incidence of EVD was peaking in Liberia. Methods We initiated a …